What Are Oncoproteins and How Do They Cause Cancer?

Oncoproteins are altered or overactive versions of normal cellular proteins that push cells toward uncontrolled growth, the defining feature of cancer. They arise when certain genes, called proto-oncogenes, pick up mutations, get duplicated too many times, or get shuffled to the wrong part of a chromosome. The normal versions of these proteins handle essential jobs like telling a cell when to divide, when to stop, and when to self-destruct. Once those proteins malfunction, cells lose the brakes and the gas pedal gets stuck. The specific ways that happens are surprisingly varied, from a single swapped letter in a gene’s code to entire chunks of chromosomes trading places.

From Normal Protein to Oncoprotein

Every oncoprotein starts as something useful. Proto-oncogenes encode proteins involved in cell signaling, growth, and survival. They are not dangerous in their normal state. The trouble begins when something alters the gene or its regulation so that the resulting protein is either structurally changed, produced in excessive amounts, or switched on permanently. Three main routes make that happen.

The first is a point mutation, a change in just one or a few letters of the DNA code. That small change can reshape the protein enough to lock it into an always-on state. The second route is gene amplification, where a cell ends up with extra copies of a proto-oncogene. More copies mean more protein, and too much of a growth-promoting protein overwhelms the cell’s normal checks. The third is chromosomal translocation, where a piece of one chromosome breaks off and attaches to another. This can place a proto-oncogene next to a powerful regulatory element that cranks up its expression, or it can fuse two genes together to create an entirely new hybrid protein with abnormal activity.¹ All three routes converge on the same outcome: a protein that drives the cell to grow and divide when it should not.²

RAS and the Stuck Switch

One of the best-studied oncoproteins is RAS, a small signaling protein that acts like a molecular switch. In healthy cells, RAS flips on when a growth signal arrives and then quickly flips itself back off by breaking down a molecule called GTP. Certain mutations, especially at positions 12 and 61 of the protein, cripple this self-off mechanism. The protein can no longer break down GTP efficiently, even when helper proteins try to assist, so it stays locked in the “on” position and keeps sending growth signals nonstop.³

Structural studies have revealed why these particular mutations are so effective at jamming the switch. Position 12 sits right in the active site where GTP gets broken down. Even swapping in a slightly larger amino acid at that spot physically blocks the molecular machinery needed to complete the reaction.⁴ RAS mutations appear in a huge fraction of human cancers, which is one reason this protein has been a top research target for decades.

Receptor Proteins That Never Stop Listening

Another major class of oncoproteins involves receptor proteins that sit on the cell surface and normally wait for an external growth signal before activating. When these receptors pick up mutations, they can fire without ever receiving a signal. The HER2 receptor is a well-known example in breast cancer. Certain mutations in HER2’s internal signaling region cause it to stay permanently active, continuously sending survival and invasion signals into the cell. One particularly potent mutation not only locks HER2 into an always-on state but also activates a neighboring receptor called EGFR, compounding the growth signal.⁵

EGFR itself is another receptor that becomes oncogenic when mutated, especially in lung cancers. These mutant receptors are attractive drug targets because they sit on the cell surface and have a well-defined pocket where drugs can bind. But as we will see later, targeting them is not as straightforward as it sounds.

The BCR-ABL Fusion Protein

Chronic myeloid leukemia provides one of the clearest examples of how a chromosomal translocation creates an oncoprotein. In this disease, a piece of chromosome 9 swaps places with a piece of chromosome 22. The break points land right inside two genes, BCR and ABL, stitching them together into a single fusion gene that produces a hybrid protein called BCR-ABL.⁶ The normal ABL protein has a built-in off switch for its signaling activity. The fusion with BCR strips that off switch away, leaving a permanently active enzyme that drives white blood cells to multiply out of control.

BCR-ABL became one of the great success stories in cancer treatment. Researchers developed imatinib, a drug designed specifically to block BCR-ABL’s activity. It transformed chronic myeloid leukemia from a near-certain death sentence into a manageable condition for most patients.⁷ The story of BCR-ABL and imatinib established the template for what oncologists now call targeted therapy: find the oncoprotein, understand its structure, and design a molecule to shut it down.

MYC and the Master Control Room

Not all oncoproteins sit at the cell surface or relay signals through the interior. Some operate inside the nucleus, directly controlling which genes get turned on. MYC is the most prominent of these. It is a transcription factor, meaning it binds to DNA and helps dictate the activity of thousands of other genes. When MYC is overactive, it cranks up programs for building cellular machinery, generating energy, and pushing cells through division.⁸

MYC abnormalities show up in the vast majority of human cancers, making it arguably the most common oncoprotein of all. High levels of MYC in tumor cells cause what researchers describe as transcriptional amplification: the cell’s existing gene expression program gets turned up across the board, flooding the cell with the building blocks it needs to grow.⁹ Activated MYC promotes the assembly of ribosomes, the molecular machines that build new proteins, which in turn fuels cell growth and proliferation.¹⁰

Despite its central role, MYC has been notoriously difficult to drug. It lacks the kind of well-defined pocket that small molecules typically latch onto, which has earned it a reputation as “undruggable.” Researchers are now exploring creative workarounds, including degrading the protein itself rather than trying to block its activity.

Blocking Cell Death

Oncoproteins do not always work by accelerating growth. Some cause cancer by preventing the cell’s built-in self-destruct program, known as apoptosis. Healthy cells that accumulate too much damage are normally eliminated through apoptosis, which functions as a critical safeguard against cancer. The BCL-2 protein family is the main gatekeeper of this process. When pro-survival members of the BCL-2 family are overproduced, or when their pro-death counterparts are suppressed, cells that should die instead survive and keep dividing.¹¹

BCL-2 was actually one of the first oncoproteins discovered that did not directly promote growth. Instead, it shields damaged cells from destruction. In prostate cancer, for example, overexpression of BCL-2 protects cancer cells from a range of death signals and correlates with the ability to form tumors that resist hormone therapy.¹² Drugs targeting BCL-2, such as venetoclax, have become important treatments in certain blood cancers, demonstrating that blocking an anti-death oncoprotein can be just as effective as blocking a pro-growth one.

Rewiring Metabolism

Cancer cells are famous for consuming glucose at much higher rates than normal cells, even when plenty of oxygen is available, a phenomenon sometimes called the Warburg effect. Oncoproteins play a direct role in rewiring cellular metabolism to support this greedy behavior. Key oncogenic drivers like MYC, RAS, and EGFR orchestrate shifts in how cells process sugars, fats, and amino acids, giving cancer cells a survival advantage in the often nutrient-poor interior of a tumor.¹³

Some less well-known oncoproteins contribute to metabolic reprogramming in specific ways. The oncoprotein HBXIP, for instance, boosts glucose consumption and lactate production in breast cancer cells by suppressing proteins that normally guide the cell toward efficient energy production.¹⁴ The broader pattern is that oncogenic signaling pathways converge on metabolism, tuning it to provide the raw materials tumors need to grow.¹⁵

A particularly striking example involves mutations in the IDH enzymes. Mutant IDH loses its normal function and gains an entirely new one: producing an abnormal metabolite that interferes with how cells read their own DNA, disrupting the chemical tags that control gene expression. This epigenetic disruption can lock cells in an immature state where they keep dividing instead of maturing into specialized tissue.¹⁶¹⁷ IDH mutations are common in certain brain tumors and some leukemias, and drugs targeting mutant IDH are already in clinical use.

Viral Oncoproteins

Not all oncoproteins come from the body’s own mutated genes. Certain viruses carry genes that encode their own oncoproteins. High-risk strains of human papillomavirus produce two proteins, E6 and E7, that dismantle the cell’s main tumor-suppression systems. E6 drives the destruction of p53, the protein most often called the “guardian of the genome,” removing a critical checkpoint that would otherwise trigger cell death or repair when DNA is damaged.¹⁸

What makes viral oncoproteins especially interesting from a structural standpoint is that they tend to be unusually flexible. E7, for instance, has a large segment that lacks a fixed three-dimensional shape, which gives it the ability to interact with a wide variety of cellular targets. This structural disorder allows the viral protein to hijack multiple pathways at once. Researchers have found that high-risk HPV strains specifically have more of this disorder in E6 and E7 than low-risk strains, suggesting the flexibility itself is part of what makes them dangerous.¹⁹²⁰

Feeding the Tumor Through New Blood Vessels

Once a tumor reaches a certain size, it needs its own blood supply. Several oncoproteins contribute to angiogenesis, the growth of new blood vessels. Oncogenic signaling can tip the balance between pro- and anti-angiogenic signals, with VEGF (vascular endothelial growth factor) being the most prominent pro-angiogenic molecule. Besides building new vasculature, VEGF also suppresses the activity of immune cells that would otherwise attack the tumor, giving cancer a double advantage.²¹ Drugs that block VEGF signaling, such as bevacizumab, are used across multiple cancer types to starve tumors of their blood supply.

Why Targeted Drugs Sometimes Stop Working

Drugs designed to block specific oncoproteins have transformed cancer treatment, but resistance is a persistent problem. The story of EGFR-targeted therapy in lung cancer illustrates this vividly. Patients whose tumors carry activating EGFR mutations often respond dramatically to drugs like gefitinib or erlotinib. But within a year or two, many tumors develop a second mutation, called T790M, in the same gene. This second mutation increases the protein’s grip on ATP, the molecule that competes with the drug for the same binding site, making the drug far less effective.²²²³

This kind of resistance mutation is not unique to EGFR. Similar gatekeeper mutations have been found in BCR-ABL and the KIT receptor, all involving a change at a structurally equivalent position near the drug-binding pocket.²⁴ Cancer cells can also sidestep a targeted drug by activating alternative signaling pathways that accomplish the same growth-promoting result through a different route, a phenomenon researchers call bypass signaling.²⁵ This is why oncologists increasingly use drug combinations or sequential therapies rather than relying on a single agent.

Degrading Oncoproteins Instead of Blocking Them

The limitations of traditional inhibitors, especially against proteins like MYC and mutant RAS that lack easy-to-target binding pockets, have pushed researchers toward a fundamentally different strategy: destroying the oncoprotein entirely rather than just blocking its activity. A technology called PROTACs (proteolysis-targeting chimeras) works by tagging the unwanted protein for disposal through the cell’s own recycling machinery. Because the PROTAC molecule can detach and tag another copy of the target, it works at much lower doses than a conventional drug that has to physically occupy every copy of the protein at once.²⁶

PROTAC-based approaches are especially promising for the RAS pathway, where traditional small-molecule inhibitors have struggled. Targeted degradation strategies could potentially overcome the resistance mutations that plague conventional drugs by eliminating the protein rather than trying to outcompete its natural binding partners.²⁷ Several PROTAC compounds are in clinical trials, though the technology is still in its early stages.

Why Childhood Cancers Play by Different Rules

The oncoproteins driving cancer in children look quite different from those in adults. Pan-cancer genomic analyses have revealed that pediatric tumors generally carry far fewer mutations overall. The driver genes in childhood cancers tend to fall into categories like transcription regulation and epigenetic control, with limited overlap with the most commonly mutated genes in adult cancers.²⁸ Pediatric cancers often arise from developing tissues, and their oncogenic changes tend to disrupt the normal process of cell maturation rather than simply accelerating cell division.²⁹

This distinction has real treatment implications. Drugs designed to target the oncoproteins common in adult cancers, like EGFR inhibitors or RAS pathway drugs, are often irrelevant for pediatric patients whose tumors are driven by entirely different molecular machinery. It also means that childhood cancer research requires its own dedicated effort rather than simply borrowing from adult oncology.

Oncoproteins as Diagnostic Tools

Beyond their role as drug targets, oncoproteins are increasingly used as biomarkers to detect and monitor cancer. MYC, for example, has been found to be deregulated in up to roughly 70% of human cancers, making it a potentially useful blood-based marker. Researchers have developed sensitive assays capable of detecting MYC protein in real blood samples, opening the door to liquid biopsies that could catch cancers or track their progression without invasive tissue sampling.³⁰ The same logic applies to other oncoproteins: because they are often produced at abnormally high levels specifically by cancer cells, their presence in blood or other body fluids can serve as a red flag that something is wrong. This approach is still maturing, but the idea of using the cancer’s own molecular signature against it is one of the more promising directions in early detection.